ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
FDA Approves Lybalvi (olanzapine and samidorphan) for the Treatment of Schizophrenia and Bipolar I Disorder
June 02, 2021ALKS today announced thathas approved Lybalvi for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes. -
FDA approves Alkermes’ Lybalvi for schizophrenia treatment
June 02, 2021The US Food and Drug Administration (FDA) has approved Alkermes’ Lybalvi as a treatment for adults with schizophrenia and for bipolar I disorder as maintenance monotherapy.
Pharma Sources Insight January 2025
